Adderall ER 20 mg: Clinical Overview
Adderall ER (extended-release mixed amphetamine salts) 20 mg is a first-line stimulant medication for ADHD that works by inhibiting dopamine and norepinephrine reuptake, providing 12-hour symptom control with once-daily morning dosing.
Indications
Adderall ER is FDA-approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children (≥6 years), adolescents, and adults 1. Stimulants are recommended as first-line pharmacological therapy for ADHD, with the largest effect sizes for reducing core ADHD symptoms 2.
When to Initiate Treatment
- Severe ADHD cases should be offered pharmacological treatment 2
- Moderate severity cases can be offered treatment based on level of suffering, family situation, comorbidities, and psychosocial functioning 2
- Always combine with behavioral interventions and psychoeducation 2
- In preschool children (<6 years), use behavioral interventions first; pharmacotherapy only for very high severity 2
Dosing Regimen
Starting Dose
- Begin with 10 mg once daily in the morning (not 20 mg initially) 3
- The 20 mg dose represents a titrated dose, not a starting dose
Titration Schedule
Week-by-week escalation:
- Week 1: 10 mg daily
- Week 2: 20 mg daily (if needed)
- Week 3: 30 mg daily (if needed)
- Week 4: 40 mg daily (if needed)
Dosing Considerations
- Single morning dose provides 12-hour coverage 5, 6
- Onset of action within 1.5 hours 5
- Maximum recommended daily dose: 40 mg for amphetamines 3
- For children <25 kg: use lower maximum doses (up to 35 mg total daily) 3
- Titrate based on symptom response and tolerability, not body weight alone 3
Monitoring During Titration
At each visit, assess:
- Height and weight (growth suppression risk) 2
- Blood pressure and pulse (cardiovascular effects) 2
- ADHD rating scales from parents and teachers 3
- Adverse effects 3
Contraindications
Absolute Contraindications
- Concomitant use with MAO inhibitors (risk of hypertensive crisis and cerebrovascular accident) 3
- Active psychosis or schizophrenia (stimulants are psychotomimetic) 3
- Glaucoma (may increase intraocular pressure) 3
Relative Contraindications (Use with Caution)
- Serious cardiac disease - screen for structural cardiac abnormalities before initiating 1
- Unstable mood disorder (can produce dysphoria) 3
- History of stimulant abuse (requires closer monitoring, not absolute contraindication) 3
NOT Contraindications (Despite Package Insert Warnings)
- Motor tics or Tourette's syndrome (controlled studies show methylphenidate does not worsen tics) 3
- Controlled anxiety disorder (improves with treatment) 3
- Controlled seizure disorder (stabilize on anticonvulsants first, then may use stimulants) 3
Common Adverse Effects
Most Frequent (from clinical trials)
In order of frequency:
- Decreased appetite/anorexia (25-36%) 7, 4
- Insomnia (12-20%) 7, 4
- Headache (16-19%) 7, 4
- Abdominal pain (11%) 7, 4
- Weight loss (9%) 4
Cardiovascular Effects
- Increased blood pressure and pulse (monitor at each visit) 2
- Most changes are statistically but not clinically significant 6, 4
Growth Effects
- Monitor height and weight at every visit 2
- Long-term growth suppression possible in pediatric patients 1
Psychiatric Effects
Key Clinical Pearls
Advantages of Extended-Release Formulation
- Once-daily dosing improves adherence 5
- Eliminates need for school-based dosing 5
- Consistent 12-hour coverage (demonstrated at 4- and 12-hour post-dose assessments) 6
- Rapid onset within 1.5 hours 5
Common Pitfalls to Avoid
- Starting at 20 mg - always begin at 10 mg and titrate 3
- Inadequate monitoring - must assess height, weight, BP, and pulse regularly 2
- Stopping at first stimulant failure - if no response to amphetamines, try methylphenidate (90% respond to one or the other) 3
- Ignoring comorbidities - stimulants also improve oppositional defiant disorder and conduct disorder 2
Treatment Response
- Expect rapid improvement within first week 6, 4
- Effect size of 0.8 in adults 6
- Dose-response relationship exists, particularly in severe cases 6
- If inadequate response after proper titration, switch to methylphenidate before trying non-stimulants 2